## Copper-Assisted/Copper-Free Synthesis of Functionalized Dibenzo[*b*,*f*]oxepins and Their Analogs *via* a One-Pot Tandem Reaction

by Yuqin Wang, Yanhong Chen, Qian He, Yuyuan Xie, and Chunhao Yang\*

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, SIBS, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China (e-mail: chyang@simm.ac.cn)

A simple, convenient, and efficient method for the formation of functionalized dibenzo[ $b_i$ f]oxepins and their analogs bearing both electron-donating and electron-withdrawing groups has been developed via a one-pot cascade reaction. Most starting materials are commercially available 2-(2-hydroxyphenyl)acetonitriles and 2-haloarylaldehydes. The procedure makes use of Cs<sub>2</sub>CO<sub>3</sub> as the base, and DMF as solvent under copper-assisted/copper-free conditions. The reaction has a comprehensive group tolerance for substrates. Most of the reactions were complete within 1 h in good-to-excellent yields, and the reaction temperatures were relatively low. The protocol could be scaled up to grams without lowering the yield. A reaction mechanism was also proposed.

**Introduction.** – Dibenzo[b,f]oxepin is an important framework in medicinal chemistry, and its derivatives occur in several medicinally relevant plants [1-6]. The scaffold has attracted considerable attention due to its diverse biological features such as anti-estrogenic [7], antidepressant [7–9], analgesic [10], anti-inflammatory [3][11][12], antipsychotic [12–15], angiotensin II receptor antagonistic [16], antioxidant [17], antimycobacterial [4], antidiabetic [18], and antitumor activities [6], as well as anti-apoptosis [19] properties (*Fig.*). The treatment of progressive neurodegenerative diseases [20] such as *Parkinson*'s and *Alzheimer*'s diseases [21] with synthetic dibenzo[b,f]oxepine derivatives is of particular interest.

Considerable efforts have been made to synthesize the dibenzo [b, f] oxepin skeleton since the report of Manske and Ledingham [22][23]. The most widely applied approaches to the synthesis of the scaffold involved constructing substrates in multiple steps via the Ullmann coupling reaction and the Friedel-Crafts reaction (Scheme 1, *Examples A* [17] and *B* [10] [11] [20] [24]), but the total yields were not satisfying. *Yang* et al. reported a method via benzoin condensation to prepare dibenzo[b,f]oxepine by using the hypertoxic reagent KCN, and obtained the product in low yield (22-25%) [25]. Another reported strategy for the formation of this fused seven-membered ring involved the Wagner-Meerwein rearrangement of a number of structurally diverse 9-(1-hydroxyalkyl)xanthenes (Scheme 1, Example C [26]). This procedure required 3-5 wt-equiv. of  $P_2O_5$ , toxic benzotrifluoride as the solvent, and a long reaction time (24– 96 h) at reflux temperature and gave the products generally in low-to-moderate yields (20-56%). Recently, Cong et al. reported a Mn<sup>III</sup>-based oxidative 1,2-radical rearrangement to form dibenzo [b, f] oxepins by using a large excess of Mn(OAc)<sub>3</sub> (4 molequiv.) in boiling glacial AcOH in moderate yields as well [27]. In 2001, Chernysheva et al. [28] reported a one-pot procedure to prepare NO<sub>2</sub>-substituted dibenz[b,f]ox-

© 2013 Verlag Helvetica Chimica Acta AG, Zürich



Figure. Pharmacologically active dibenzo[b,f]oxepins

epines. However, this method involved explosive 2,4,6-trinitrotoluene as the starting reagent. These existing methods have some inherent disadvantages, *i.e.*, *i*) multiple synthetic steps, *ii*) low total yields, *iii*) harsh and not environment-friendly conditions, and *iv*) long reaction times, and they cannot provide fast and efficient access to a library of functionalized dibenzo[b,f]oxepins and thus limit the molecular diversity for lead optimization and drug screening. Considering the promising biological activities of dibenzo[b,f]oxepins, a facile, practical, and versatile method that enables quick access to dibenzo[b,f]oxepins is highly desirable.

Here, we report a convenient method for preparing dibenzo [b,f] oxepins with various functional groups *via* a one-pot cascade reaction in good-to-excellent yields under Cu-assisted as well as Cu-free conditions.

**Results and Discussion.** – We started with commercially available 2-bromobenzaldehyde (**2a**) and 2-(2-hydroxyphenyl)acetonitrile (**1a**), which was prepared from 2-(2methoxyphenyl)acetonitrile by deprotection of the methyl ether group with BBr<sub>3</sub> [29], as the model reaction. First, the reaction was catalyzed by CuI in dioxane and K<sub>2</sub>CO<sub>3</sub> as the base at 100° (*Table 1, Entry 1*). The desired compound **3a** was obtained only in 20% yield. When DMF was used as the solvent, the reaction proceeded smoothly, resulting in an 88% yield (*Table 1, Entry 2*). Next, the bases were investigated. As shown in *Table 1*, the reaction went well with Cs<sub>2</sub>CO<sub>3</sub>, and the yield of **3a** was quite high (*Entry 6*). The yield was lower when DBU (=1,8-diazabicyclo[5.4.0]undec-7-ene) was used as base (*Table 1, Entry 5*), and the reaction was not complete at 100° after 5 h. With a prolonged time (12 h) and higher temperature (150°), the reaction afforded **3a** in 61% yield. The reaction did not work when EtONa and DMAP (=4-(dimethylamino)pyridine) were used as bases (*Table 1, Entries 3* and 4). Then, the loading of CuI was investigated. When the reaction was conducted in the presence of an increased Scheme 1. Reported Synthesis of Dibenzo[b,f]oxepins



amount of CuI, the yield did not improve (*Table 1, Entry 7*). When the amount of CuI was decreased to 0.05 equiv. (*Table 1, Entry 8*), a comparable yield was obtained. To our delight, 0.01 equiv. of CuI (*Table 1, Entry 9*) was as effective without a prolonged reaction time. The reaction was also studied under a Cu-free condition (*Table 1, Entry 14*). Although **3a** was obtained in 60% yield, the starting material was not completely consumed, and the yield decreased with prolonged time. Next, the amount of base was explored. By decreasing the amount of Cs<sub>2</sub>CO<sub>3</sub> (*Table 1, Entries 10* and *11*), a slightly lower yield of **3a** was obtained. Finally, when the reaction temperature was raised to 120°, the reaction was complete within 1 h, but the yield decreased (*Table 1, Entry 12*). The yield of **3a** was only 66% when the reaction was conducted at 80° (*Table 1, Entry 13*).

Under the optimal reaction conditions (0.01 equiv. of CuI, 3 equiv. of  $Cs_2CO_3$ , DMF, 100°, 1 h), we investigated the scope and limitations of the reaction employing a variety of *ortho*-haloarene-carbaldehydes and 2-(2-hydroxyphenyl)acetonitrile (**1a**). As compiled in *Table 2*, a number of 2-bromobenzaldehydes bearing both electron-donating (EDG) and electron-withdrawing groups (EWG) reacted very well. With 2-bromo-3-fluorobenzaldehyde (**2b**), the reaction proceeded smoothly with an excellent yield (*Table 2, Entry 1*). The effect of substitutions at C(4) of 2-bromobenzaldehyde

Table 1. Optimization of the Reaction Conditions<sup>a</sup>)



<sup>a</sup>) Reaction conditions: **1a** (70 mg, 0.52 mmol), **2a** (93 mg, 0.5 mmol), solvent (8 ml). <sup>b</sup>) Yield of isolated **3a**. <sup>c</sup>) The reaction required a prolonged time (17 h) and higher temperature (150°) to complete. <sup>d</sup>) The amount of product decreased with a prolonged reaction time.

was then studied. A Me or MeO group had similar effects (*Table 2, Entries 2* and 3). The substrate with an EDG such as MeO at C(5) (*Table 2, Entry 4*) gave an excellent yield, and the same results were obtained with an EWG at C(5) (*Table 2, Entries 5* and 6). However, **2h** with the potent EWG CF<sub>3</sub> group at C(5) gave a slightly lower yield (*Table 2, Entry 7*), as did the electron-deficient 2-bromonicotinaldehyde (**2l**; *Table 2, Entry 11*). The polysubstituted 2-bromo-4,5-dimethoxybenzaldehyde (**2i**) was also a suitable substrate, and the reaction could be scaled up to grams without lowering the yields (*Table 2, Entry 8*). The bulky 1-bromonaphthalene-2-carbaldehyde (**2k**) reacted just as well under the standard conditions as the other substrates (*Table 2, Entry 10*). To our delight, the reaction of the electron-rich heterocyclic 3-bromothiophene-2-carbaldehyde (**2m**) also went smoothly and gave a high yield of **3m** (*Table 2, Entry 12*). Moreover, 2-fluoro- and 2-chlorobenzaldehydes (**2n** and **2o**, resp.) were also tested as the substrates to react with **1a**, and the yields were 76 (*Table 2, Entry 13*) and 61% (*Table 2, Entry 14*), respectively.

After having investigated the scope for *ortho*-haloarene-carbaldehydes, we then studied the reactions of 2-(2-hydroxyphenyl)acetonitriles. Both substrates with EDGs and EWGs, such as 2-(2-hydroxy-3-methoxyphenyl)acetonitrile (**1b**), 2-[2-hydroxy-4-(trifluoromethyl)phenyl]acetonitrile (**1c**), and 2-(5-bromo-2-hydroxyphenyl)acetonitrile (**1d**), were tested under the optimal reaction conditions (*Table 3*). Most reactions proceeded with high yields. When **1b** was used as the substrate, the structurally

Table 2.	One-Pot	Cascade	Reaction	oj	f 2-(2-Hydroxyphenyl)acetonitrile	( <b>1</b> a)	with	Various	ortho-
				Ηd	aloarene-carbaldehydes <sup>a</sup> )				



<sup>a</sup>) Reaction conditions: **1a** (70 mg, 0.53 mmol), **2b** – **2m** (0.50 mmol),  $Cs_2CO_3$  (488 mg, 1.5 mmol), CuI (1 mg, 0.005 mmol), DMF (8 ml), reaction time (most of the reaction were complete within 1 h). <sup>b</sup>) Yield of isolated **3**. <sup>c</sup>) The reaction was scaled up to grams (**1a** (1.33 g, 10 mmol), **2i** (2.45 g, 10 mmol),  $Cs_2CO_3$  (9.78 g, 30 mmol), CuI (20 mg, 0.1 mmol), and DMF (20 ml)); 97%.

hindered MeO group of **1b** led to a decrease in the yields of the product compared with the corresponding product of **1a** (compounds **4a** – **4e**, **4h**, **4i**, and **4k** vs. compounds **3a**– **3e**, **3h**, **3i**, and **3k**), except for **4f**, **4g**, **4l**, and **4m**. Yields of **4f**, **4g**, and **4m** were slightly higher than those of **3f**, **3g**, and **3m**, but the yield of **4l** (92%) was dramatically higher than that of **3l** (65%). When **1c** was treated with various 2-bromobenzaldehydes, the EWG CF<sub>3</sub> of **1c** also led to a decrease in the yields (compounds **4n**, **4o**, and **4p** vs. compounds **3a**, **3g**, and **3e**). In the case of **1d**, substituted 2-bromobenzaldehydes, **2g** and **2e**, gave higher yields than 2-bromobenzaldehyde (*Table 3*, *Entries 17* and *18* vs. *Entry 16*). Furthermore, 2-bromobenzaldehyde with a 5-MeO group (*Table 3*, *En try 15*) underwent the reaction in excellent yield (95%), while 2-bromobenzaldehyde with a 5-Cl group led to a decreased yield (*Table 3*, *Entries 14* vs. *13*). As 2-(2aminophenyl)acetonitrile (**1d**) is an analog of **1a**, **1d** was treated with 2-bromobenzaldehyde under the standard conditions without any optimization, to give the corresponding product in only 21% yield (*Table 3*, *Entry 19*).

We also tried another strategy to construct dibenzo[b,f]oxepin under the same conditions (0.01 equiv. of CuI, 3 equiv. of Cs<sub>2</sub>CO<sub>3</sub>, DMF, 100°, 1 h; *Scheme 2*).

Table 3. One-Pot Cascade Reaction of 2-(ortho-Hydroxy/ortho-Aminophenyl)acetonitriles with Substituted 2-Bromobenzaldehydes<sup>a</sup>)

R <sup>1</sup>		:N + R <sup>2</sup>	Er 2a – 2i	- C	Cs₂CO₃ (3 equiv.) Cul (0.01 equiv.) 100°, DMF	R <sup>1</sup>	$R^{1} \xrightarrow{CN} R^{2}$ $4a - 4i, 4k - 4s x = 0$		
1b R <sup>1</sup> = 1c R <sup>1</sup> = 1d R <sup>1</sup> = 1e R <sup>1</sup> =	= 3-MeO, 1 = 4-CF <sub>3</sub> , X = 5-Br, X = = H, X = N	X = OH = OH = OH H <sub>2</sub>			CHO Br	4t x = N			
Entry	1	<b>R</b> <sup>1</sup>	X	2	R <sup>2</sup>	Product	Yield [%] <sup>b</sup> )		
1	h	3-MeO	OH	я	н	49	87		
2	b	3-MeO	OH	b	3-F	4b	83		
3	b	3-MeO	OH	c	4-Me	4c	80		
4	b	3-MeO	OH	d	4-MeO	4d	71		
5	b	3-MeO	OH	е	5-MeO	<b>4</b> e	90		
6	b	3-MeO	OH	f	5-F	<b>4f</b>	98		
7	b	3-MeO	OH	g	5-Cl	4g	97		
8	b	3-MeO	OH	ĥ	$5-CF_3$	4h	70		
9	b	3-MeO	OH	i	$4,5-(MeO)_2$	4i	83		
10	b	3-MeO	OH	k		4k	80		
11	b	3-MeO	OH	1		41	92		
12	b	3-MeO	OH	m		4m	95		
13	с	$4-CF_3$	OH	a	Н	4n	72		
14	с	$4-CF_3$	OH	g	5-Cl	40	63		
15	c	$4-CF_3$	OH	e	5-MeO	4p	95		
16	d	5-Br	OH	а	Н	4q	79		
17	d	5-Br	OH	g	5-Cl	4r	92		
18	d	5-Br	OH	е	5-MeO	<b>4</b> s	86		
19	e	Н	NH <sub>2</sub>	a	Н	<b>4t</b> [30]	21		

<sup>&</sup>lt;sup>a</sup>) Reaction conditions: 1a-1d (0.53 mmol), 2a-2m (0.50 mmol),  $Cs_2CO_3$  (488 mg, 1.5 mmol), CuI (1 mg, 0.005 mmol), and DMF (8 ml). <sup>b</sup>) Yield of isolated **4**.

Unfortunately, we did not obtain any desired product. This can be explained by the mechanism of the reaction. We presumed that the cascade includes two steps: the first step is a *Knoevenagel* condensation, followed by the *Ullmann* ether formation (*Scheme 3*). This was established by formation of the same intermediates, as revealed by LC/MS, under Cu-assisted and Cu-free conditions. The intermediate in the formation of **3d** was confirmed by <sup>1</sup>H- and <sup>13</sup>C-NMR, and MS data (*Scheme 3*). This intermediate could be converted to compound **3d** *via* cyclization in two pathways. When CuI was present, *Ullmann* ether formation occurred subsequently (*Path A*), or the aromatic nucleophilic substitution reaction (*Path B*) would occur to give **3d** under Cu-free condition. However, *Path A* gave **3d** with a preponderant high yield (92%; 56%)

Scheme 2. Another Strategy to Form Dibenzo[b,f]oxepin



for *Path B*; *Table 1*, *Entries 9* and *14*). When salicylaldehyde was used as the substrate in the presence of the base, the phenoxy anion decreased the activity of aldehyde, and *Knoevenagel* condensation could not occur under our conditions.

**Conclusions.** – We have developed a simple and efficient method for the synthesis of the pharmacologically important dibenzo[b,f]oxepin scaffold via Cu-assisted/Cu-free one-pot tandem reaction. Various substituted 2-(2-hydroxyphenyl)acetonitriles and substituted 2-haloarene-carbaldehydes are tolerated well in the reaction. By this procedure, a library of functionalized dibenzo[b,f]oxepins was achieved quickly with good-to-excellent yields. This approach also provides a practical method, because it could be easily scaled up to grams with excellent yields. Further studies for the synthesis of novel dibenzo[b,f]oxepin analogs and their biological evaluation are currently in progress.

## **Experiment Part**

*General.* All the reagents, except **1a**, are commercially available, and they were used without further purification. Anal. TLC: *HSGF 254* (0.15–0.2 mm thickness, *Yantai Huiyou Company*, China). Column chromatography (CC): silica gel (200–300 mesh). M.p. *Büchi 510* melting-point apparatus; uncorrected. <sup>1</sup>H- and <sup>13</sup>C-NMR spectra: *Varian Mercury-300* and/or *Varian Mercury-400* spectrometers;  $\delta$  in ppm rel. to Me<sub>4</sub>Si as internal standard, *J* in Hz. LR- and HR-MS: *Finnigan/MAT-95* spectrometer.

2-(2-Hydroxyphenyl) acetonitrile (1a) [29]. The corresponding 2-(2-methoxyphenyl) acetonitrile was dissolved in anh. CH<sub>2</sub>Cl<sub>2</sub>, followed by slowly adding of 4N BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> (4-5 equiv.) at 0°. The mixture was stirred at r.t. for a few h, then poured onto crushed ice, and the white precipitate was collected by filtration. The product was obtained as white solid.

General Procedure for 3a-3m, 4a-4i, and 4k-4s. To a mixture of 1 (0.53 mmol) and 2bromobenzaldehyde 2 (0.5 mmol) in a 25-ml two-necked reaction flask were added Cs<sub>2</sub>CO<sub>3</sub> (1.5 mmol), CuI (0.005 mmol), and DMF (8 ml). The mixture was degassed with Ar (3 ×) and then heated at 100° for 0.5-1 h. Most of the reactions were complete within 1 h. Once the reaction was completed (monitored by TLC), the mixture was poured onto crushed ice and then extracted with AcOEt (3 ×). The combined org. layers were washed with brine and dried (Na<sub>2</sub>SO<sub>4</sub>). Concentration and purification by CC afforded the products with desirable purities.

3-(2-Bromo-4-methoxyphenyl)-2-(2-hydroxyphenyl)prop-2-enenitrile (the intermediate in Scheme 3). Yellow lamellar crystals. M.p. 154–155°. <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 10.36 (s, 1 H); 7.96 (d, J = 8.8, 1 H); 7.89 (s, 1 H); 7.40 (dd, J = 7.7, 1.5, 1 H); 7.35 (d, J = 2.6, 1 H); 7.25 (td, J = 7.8, 1.6, 1 H); 7.13 (dd, J = 8.8, 2.6, 1 H); 6.97–6.87 (m, 2 H); 3.83 (s, 3 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 161.44, 155.55, 144.14 (CH); 130.99 (CH); 130.78 (CH); 129.97 (CH); 126.80, 125.60, 121.26, 120.09 (CH); 118.60 (CH); 117.94, 116.82 (CH); 114.54 (CH); 110.70, 56.36 (Me). EI-MS: 329, 331 (40,  $M^+$ ), 250 (100, [M - Br]<sup>+</sup>). HR-EI-MS: 329.0033 ( $M^+$ , C<sub>16</sub>H<sub>12</sub>BrNO<sup>+</sup><sub>2</sub>; calc. 329.0051).

*Dibenzo*[b,f]*oxepine-10-carbonitrile* (**3a**). Compound **3a** was obtained after the purification by flash chromatography (FC; SiO<sub>2</sub>, 200–300 mesh; petroleum ether (PE)/AcOEt 100:1). Yellowish needles. M.p. 159–160° ([31]: 159–160°). IR (KBr): 2219.67 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.92 (*s*, 1 H); 7.60–7.48 (*m*, 4 H); 7.42–7.27 (*m*, 4 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 158.00; 157.22; 143.85; 133.90; 132.85; 131.45; 128.18; 126.55; 126.21; 126.12; 122.54; 121.94; 118.76; 112.75. EI-MS: 219 (*M*<sup>+</sup>, 100). HR-EI-MS: 219.0681 (*M*<sup>+</sup>, C<sub>15</sub>H<sub>9</sub>NO<sup>+</sup>; calc. 219.0684).

*4-Fluorodibenzo[b,f]oxepine-10-carbonitrile* (**3b**). Compound **3b** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). White powder. M.p. 207–208°. IR (KBr): 2219.67 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 8.00 (*s*, 1 H); 7.63–7.49 (*m*, 3 H); 7.44–7.26 (*m*, 4 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 156.98; 153.91 (*d*, J = 248, C–F); 144.69 (*d*, J = 14, C–C–F); 142.95 (*d*, J = 4, C–C–C–F); 133.18; 130.51; 128.63; 127.06; 126.84 (*d*, J = 8, C–C–C–F); 126.73 (*d*, J = 4, C–C–C–C–F); 126.01; 122.46; 120.22 (*d*, J = 17.6, C–C–F); 118.51; 113.70. EI-MS: 237 (M<sup>+</sup>, 100). HR-EI-MS: 237.0593 (M<sup>+</sup>, C<sub>15</sub>H<sub>8</sub>FNO<sup>+</sup>; calc. 237.0590).

*3-Methyldibenzo[b*,f*]oxepine-10-carbonitrile* (**3c**). Compound **3c** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 70:1). Yellowish powder. M.p. 139–140°. IR (KBr): 2213.88 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.87 (*s*, 1 H); 7.58–7.47 (*m*, 2 H); 7.36 (*m*, 3 H); 7.20 (*s*, 1 H); 7.12 (*d*, J = 7.7, 1 H); 2.34 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 157.50; 156.60; 144.35; 143.34; 132.17; 130.77; 127.62; 126.38; 125.99; 125.81; 125.00; 122.07; 121.87; 118.44; 111.30; 20.83. EI-MS: 233 (*M*<sup>+</sup>, 100). HR-EI-MS: 233.0833 (*M*<sup>+</sup>, C<sub>16</sub>H<sub>11</sub>NO<sup>+</sup>; calc. 233.0841).

*3-Methoxydibenzo*[b,f]*oxepine-10-carbonitrile* (**3d**). Compound **3d** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 40:1). Yellowish powder. M.p. 149–150°. IR (KBr): 2211.95 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.81 (*s*, 1 H); 7.55–7.30 (*m*, 5 H); 6.99 (*d*, J = 2.2, 1 H); 6.88 (*dd*, J = 8.6, 2.4, 1 H); 3.82 (*s*, 3 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 164.39; 159.47; 156.54; 143.70; 132.66; 132.43; 127.92; 126.56; 126.50; 122.69; 120.92; 119.18; 112.41; 109.88; 107.52; 56.33. EI-MS: 249 ( $M^+$ , 100). HR-EI-MS: 249.0788 ( $M^+$ , C<sub>16</sub>H<sub>11</sub>NO<sub>2</sub><sup>+</sup>; calc. 249.0790).

2-*Methoxydibenzo*[b,f]*oxepine-10-carbonitrile* (**3e**). Compound **3e** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 60:1). Yellowish powder. M.p. 171–172°. IR (KBr): 2210.02 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.86 (*s*, 1 H); 7.58–7.48 (*m*, 2 H); 7.39–7.31 (*m*, 2 H); 7.28 (*d*, J = 8.4, 1 H); 7.13–7.06 (*m*, 2 H); 3.74 (*s*, 3 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 157.13; 156.39; 151.27; 143.26; 132.42; 128.29; 127.78; 125.95; 125.63; 122.26; 121.92; 118.72; 118.35; 114.86; 112.66; 55.65. EI-MS: 249 ( $M^+$ , 100). HR-EI-MS: 249.0792 ( $M^+$ , C<sub>16</sub>H<sub>11</sub>NO<sub>2</sub><sup>+</sup>; calc. 249.0790).

2-*Fluorodibenzo[*b,f*]oxepine-10-carbonitrile* (**3f**). Compound **3f** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). Yellowish powder. M.p. 218–219°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.86 (*s*, 1 H); 7.63–7.47 (*m*, 2 H); 7.47–7.29 (*m*, 5 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 158.86 (*d*, J = 243, CF); 156.77; 153.74; 142.03; 132.68; 129.05 (*d*, J = 9, C–CH–C–F);

127.88; 126.21; 125.42; 123.18 (d, J = 9, CH–CH–C–F); 121.99; 119.72 (d, J = 24, CH–C–F); 118.01; 116. 68 (d, J = 24, CH–C–F); 113.54. EI-MS 237 (M<sup>+</sup>, 100). HR-EI-MS: 237.0591 (M<sup>+</sup>, C<sub>15</sub>H<sub>8</sub>FNO<sup>+</sup>; calc. 237.0590).

2-*Chlorodibenzo[*b,f*]oxepine-10-carbonitrile* (**3g**). Compound **3g** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). White powder. M.p. 197–198°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.86 (*s*, 1 H); 7.63–7.50 (*m*, 4 H); 7.42–7.33 (*m*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 156.59; 156.23; 141.86; 132.76; 132.72; 130.11; 129.65; 129.32; 127.92; 126.32; 125.37; 123.31; 122.08; 117.98; 113.60. EI-MS: 253 (*M*<sup>+</sup>, 100). HR-EI-MS: 253.0302 (*M*<sup>+</sup>, C<sub>15</sub>H<sub>8</sub>CINO<sup>+</sup>; calc. 253.0294).

2-(*Trifluoromethyl*)*dibenzo*[b,f]*oxepine-10-carbonitrile* (**3h**). Compound **3h** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). White powder. M.p. 107–108°. IR (KBr): 2223.52 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.99–7.89 (*m*, 3 H); 7.63–7.52 (*m*, 3 H); 7.47–7.35 (*m*, 2 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 160.58; 156.77; 142.43 (CH); 133.36 (CH); 130.65 (*d*, J=2.5, CH–C–CF<sub>3</sub>); 128.95; 128.75 (*d*, J=2.5, CH–C–CF<sub>3</sub>); 128.48 (CH); 127.05 (CH); 126.68 (*d*, J=33, C–CF<sub>3</sub>); 125.80; 125.14; 123.25 (CH); 122.98; 122.71 (CH); 118.39. EI-MS: 287 (*M*<sup>+</sup>, 100). HR-EI-MS: 287.0554 (*M*<sup>+</sup>, C<sub>16</sub>H<sub>8</sub>F<sub>3</sub>NO<sup>+</sup>; calc. 287.0558).

2,3-Dimethoxydibenzo[b,f]oxepine-10-carbonitrile (**3i**). Compound **3i** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 10:1). Yellow powder. M.p. 157–158°. IR (KBr): 2208.09 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.76 (*s*, 1 H); 7.57–7.45 (*m*, 2 H); 7.40–7.30 (*m*, 2 H); 7.07 (*s*, 1 H); 7.05 (*s*, 1 H); 3.84 (*s*, 3 H); 3.74 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 156.87; 153.46; 152.38; 146.45; 143.71; 132.37; 127.77; 126.44; 126.30; 122.43; 119.60; 119.12; 112.87; 110.28; 105.86; 56.41; 56.29. EI-MS: 279 ( $M^+$ , 100). HR-EI-MS: 279.0905 ( $M^+$ , C<sub>17</sub>H<sub>13</sub>NO<sub>3</sub><sup>+</sup>; calc. 279.0895).

[1,3]Dioxolo[4',5':4,5]benzo[1,2-b]benzo[f]oxepine-10-carbonitrile (=1,3,5-Trioxabenzo[4,5]cyclohept[1,2-f]indene-10-carbonitrile;**3j**). Compound**3j**was obtained after the purification by FC (SiO<sub>2</sub>;PE/AcOEt 50:1). Yellow powder. M.p. 199–200°. IR (KBr): 2219.67 (CN). <sup>1</sup>H-NMR (300 MHz,(D<sub>6</sub>)DMSO): 7.74 (*s*, 1 H); 7.57–7.45 (*m*, 2 H); 7.33 (*dd*,*J*= 9.0, 3.0, 2 H); 7.08 (*s*, 1 H); 7.02 (*s*, 1 H); 6.11(*s*, 2 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 156.14; 153.03; 151.60; 144.96; 143.13; 132.18; 127.28;126.10; 126.06; 121.90; 120.69; 118.61; 110.25; 108.32; 103.16; 102.71. EI-MS: 263 (*M*<sup>+</sup>, 100). HR-EI-MS:263.0584 (*M*<sup>+</sup>, C<sub>16</sub>H<sub>9</sub>NO<sub>3</sub><sup>+</sup>; calc. 263.0582).

*Benzo*[b]*naphtho*[2,1-f]*oxepine-8-carbonitrile* (**3k**). Compound **3k** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 50:1). Yellow powder. M.p. 223–224°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 8.67 (*d*, J = 7.6, 1 H); 8.07 (*s*, 1 H); 8.01 (*d*, J = 7.5, 1 H); 7.83 (*d*, J = 8.5, 1 H); 7.7–7.52 (*m*, 6 H); 7.42–7.348 (*t*, J = 7.5, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 156.57; 153.20; 143.76; 135.71; 132.73; 128.39; 127.90; 127.80; 126.00; 126.50; 126.22; 125.12; 123.26; 122.71; 122.17; 118.31; 112.84. EI-MS: 269 (*M*<sup>+</sup>, 100). HR-EI-MS: 269.0839 (*M*<sup>+</sup>, C<sub>19</sub>H<sub>11</sub>NO<sup>+</sup>; calc. 269.0841).

*Benzo*[6,7]*oxepino*[2,3-b]*pyridine-6-carbonitrile* (=[1]*Benzoxepino*[2,3-b]*pyridine-6-carbonitrile*; **31**). Compound **31** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 5:1). White powder. M.p. 207–208°. IR (KBr): 2219.67 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 8.43 (d, J = 2.2, 1 H); 8.03 (d, J = 7.5, 1 H); 7.92 (s, 1 H); 7.64–7.53 (m, 2 H); 7.45–7.35 (m, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 161.14; 155.56; 151.70; 141.86; 141.59; 133.34; 128.40; 126.98; 125.48; 123.12; 123.08; 122.77; 118.41; 113.77. EI-MS: 220 ( $M^+$ , 100). HR-EI-MS: 220.0633 ( $M^+$ , C<sub>14</sub>H<sub>8</sub>N<sub>2</sub>O<sup>+</sup>; calc. 220.0637).

*Benzo*[b]*thieno*[2,3-f]*oxepine-9-carbonitrile* (= *Thieno*[3,2-b][1]*benzoxepine-9-carbonitrile*; **3m**). Compound **3m** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 5:1). Yellow powder. M.p. 159–160°. IR (KBr): 2213.88 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 8.00 (d, J = 4.6, 1 H); 7.83 (s, 1 H); 7.61–7.43 (m, 2 H); 7.40–7.33 (m, 1 H); 7.22 (d, J = 8.1, 1 H); 7.02 (d, J = 4.7, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 158.10; 156.03; 136.89; 133.42; 132.56; 128.39; 126.23; 126.04; 121.92; 121.72; 121.65; 118.51; 109.41. EI-MS: 225 ( $M^+$ , 100). HR-EI-MS: 225.0240 ( $M^+$ , C<sub>13</sub>H<sub>7</sub>NOS<sup>+</sup>; calc. 225.0248).

*6-Methoxydibenzo*[b,f]*oxepine-10-carbonitrile* (**4a**). Compound **4a** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 60:1). Yellowish powder. M.p. 171–172°. IR (KBr): 2210.02 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.93 (*s*, 1 H); 7.58–7.48 (*m*, 2 H); 7.33–7.24 (*m*, 4 H); 7.06 (*m*, 1 H); 3.90 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 157.54; 151.89; 144.61; 143.42; 133.24; 130.84; 128.13; 126.85; 126.12; 125.65; 121.69; 118.39; 114.96; 112.35; 56.25. EI-MS: 249 ( $M^+$ , 100). HR-EI-MS: 249.0799 ( $M^+$ , C<sub>16</sub>H<sub>11</sub>NO<sup>+</sup><sub>2</sub>; calc. 249.0790).

*4-Fluoro-6-methoxydibenzo*[b,f]*oxepine-10-carbonitrile* (**4b**). Compound **4b** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). Yellowish powder. M.p. 248–249°. IR (KBr): 2219.67 (CN). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): 7.46 (*s*, 1 H); 7.28–7.23 (*m*, 1 H); 7.19–7.11 (*m*, 3 H); 7.11–7.05 (*m*, 1 H); 7.02 (*d*, J = 7.7, 1 H); 3.96 (*s*, 3 H). <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>): 155.74 (*d*, J = 252, CF); 153.65; 147.51; 147.27 (*d*, J = 13.9, C-C-F); 143.18 (*d*, J = 3.8, CH-CH-CH-C-F); 132.17; 128.78; 127.58 (CH); 127.16 (*d*, J = 7.6, CH-CH-C-F); 126.69 (*d*, J = 3.8, CH-C-C-C-F); 121.13 (*d*, J = 20.2, CH-C-F); 121.15 (CH); 119.80; 116.57; 116.48 (CH); 58.00 (Me). EI-MS: 267 (*M*<sup>+</sup>, 100). HR-EI-MS: 267.0694 (*M*<sup>+</sup>, C<sub>16</sub>H<sub>10</sub>FNO<sub>2</sub><sup>+</sup>; calc. 267.0696).

6-*Methoxy-3-methyldibenzo*[b,f]*oxepine-10-carbonitrile* (**4c**). Compound **4c** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 20 : 1). Yellowish powder. M.p. 164–165°. IR (KBr): 2215.81 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.87 (*s*, 1 H); 7.38 (*d*, *J* = 7.7, 1 H); 7.27–7.24 (*m*, 2 H); 7.12 (*s*, 1 H); 7.10 (*d*, *J* = 7.7, 1 H); 7.04 (*m*, 1 H); 3.90 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 157.51; 151.91; 144.54; 144.19; 143.44 (CH); 130.66 (CH); 126.98; 126.40 (CH); 126.09 (CH); 125.44; 122.10 (CH); 118.57; 118.36 (CH); 114.80 (CH); 111.38; 56.28 (Me); 20.93 (Me). EI-MS: 263 (*M*<sup>+</sup>, 100). HR-EI-MS: 263.0949 (*M*<sup>+</sup>, C<sub>17</sub>H<sub>13</sub>NO<sub>2</sub><sup>+</sup>; calc. 263.0946).

*3,6-Dimethoxydibenzo[b,f]oxepine-10-carbonitrile* (4d). Compound 4d was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 40 : 1). Yellowish powder. M.p. 173–174°. IR (KBr): 2211.95 (CN). <sup>1</sup>H-NMR (400 MHz, (D<sub>6</sub>)DMSO): 7.83 (*s*, 1 H); 7.44 (*d*, J = 8.7, 1 H); 7.29–7.22 (*m*, 2 H); 7.02 (*dd*, J = 6.6, 2.6, 1 H); 6.90 (*dd*, J = 8.6, 2.6, 1 H); 6.82 (*d*, J = 2.6, 1 H); 3.89 (*s*, 3 H); 3.82 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 163.66; 158.85; 151.97; 143.91; 143.21 (CH); 132.07 (CH); 127.20; 126.16 (CH); 120.91; 118.76; 118.17 (CH); 114.56 (CH); 110.49; 107.34 (CH); 56.24 (Me); 55.81 (Me). EI-MS: 279 (*M*<sup>+</sup>, 100). HR-EI-MS: 279.0888 (*M*<sup>+</sup>, C<sub>17</sub>H<sub>13</sub>NO<sub>3</sub><sup>+</sup>; calc. 279.0895).

2,6-Dimethoxydibenzo[b,f]oxepine-10-carbonitrile (4e). Compound 4e was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 40:1). Yellowish powder. M.p. 167–168°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (400 MHz, (D<sub>6</sub>)DMSO): 7.88 (*s*, 1 H); 7.27–7.25 (*m*, 2 H); 7.22 (*d*, J = 9.1, 1 H); 7.12–7.03 (*m*, 3 H); 3.89 (*s*, 3 H); 3.74 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 156.29; 151.76; 151.26; 144.95; 143.28 (CH); 128.61; 126.76; 125.96 (CH); 122.35 (CH); 118.62 (CH); 118.43 (CH); 114.98 (CH); 114.65 (CH); 112.66; 56.22 (Me); 55.64 (Me). EI-MS: 279 (M<sup>+</sup>, 100). HR-EI-MS: 279.0904 (M<sup>+</sup>, C<sub>17</sub>H<sub>13</sub>NO<sub>3</sub><sup>+</sup>; calc. 279.0895).

2-*Fluoro-6-methoxydibenzo*[b,f]*oxepine-10-carbonitrile* (**4f**). Compound **4f** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 50:1). White powder. M.p. 211–212°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.85 (*s*, 1 H); 7.40–7.23 (*m*, 5 H); 7.08–7.02 (*m*, 1 H); 3.89 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 158.77 (*d*, J = 243, C–F); 153.71; 151.80; 144.54; 142.13; 129.40 (*d*, J = 9.1, C–CH–C–F); 126.59; 126.31; 123.25 (*d*, J = 9.1, CH–CH–C–F); 119.61 (*d*, J = 24.3, CH–C–F); 118.50; 118.11; 116.59 (*d*, J = 25.2, CH–C–F); 115.29; 113.56; 56.27 (Me). EI-MS: 267 ( $M^+$ , 100). HR-EI-MS: 267.0696 ( $M^+$ , C<sub>16</sub>H<sub>10</sub>FNO<sub>2</sub><sup>+</sup>; calc. 267.0696).

*2-Chloro-6-methoxydibenzo*[b,f]*oxepine-10-carbonitrile* (**4g**). Compound **4g** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 50 : 1). Yellowish powder. M.p. 235 – 236°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.89 (*s*, 1 H); 7.65 – 7.58 (*m*, 2 H); 7.35 – 7.28 (*m*, 3 H); 7.10 – 7.04 (*m*, 1 H); 3.90 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 156.16; 151.81; 144.35; 141.92 (CH); 132.64 (CH); 130.00 (CH); 129.67; 129.55; 126.54; 126.42 (CH); 123.37 (CH); 118.53 (CH); 118.08; 115.32 (CH); 113.61; 56.29 (Me). EI-MS: 283 (*M*<sup>+</sup>, 100). HR-EI-MS: 283.0402 (*M*<sup>+</sup>, C<sub>16</sub>H<sub>10</sub>CINO<sup>+</sup><sub>2</sub>; calc. 283.0400).

6-*Methoxy-2-(trifluoromethyl)dibenzo[*b,f*]oxepine-10-carbonitrile* (**4h**). Compound **4h** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 50:1). White powder. M.p. 180–181°. IR (KBr): 2219.67 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.97 (*s*, 1 H); 7.93 (*s*, 1 H); 7.88 (*dd*, J = 8.3, 1 H); 7.47 (*d*, J = 8.4, 1 H); 7.31–7.27 (*m*, 2 H); 7.10–7.02 (*m*, 1 H); 3.90 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 160.01; 151.89; 144.00; 141.96; 130.00 (*d*, J = 3.0, CH–C–CF<sub>3</sub>); 128.82; 128.14 (*d*, J = 4.0, CH–C–CF<sub>3</sub>); 126.66; 126.38 (*d*, J = 32, *C*–CF<sub>3</sub>); 126.51; 123.59 (*d*, J = 270, CF<sub>3</sub>); 122.84; 118.57; 117.98; 115.47; 113.89; 56.33 (Me). EI-MS: 317 (*M*<sup>+</sup>, 100). HR-EI-MS: 317.0663 (*M*<sup>+</sup>, C<sub>17</sub>H<sub>10</sub>F<sub>3</sub>NO<sub>2</sub><sup>+</sup>; calc. 317.0664).

2,3,6-*Trimethoxydibenzo*[b,f]*oxepine-10-carbonitrile* (4i). Compound 4i was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 10:1). Yellow powder. M.p. 208–209°. IR (KBr): 2211.95 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.79 (*s*, 1 H); 7.28–7.24 (*m*, 2 H); 7.11 (*s*, 1 H); 7.04–7.00 (*m*, 1 H); 6.87 (*s*, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 152.87; 151.90; 151.84; 146.10; 144.41; 143.36 (CH);

127.19; 125.99 (CH); 119.66; 118.82; 118.17 (CH); 114.66 (CH); 112.35 (CH); 109.99; 105.32 (CH); 56.29 (Me); 55.92 (Me); 55.92 (Me). EI-MS: 309 ( $M^+$ , 100). HR-EI-MS: 309.0998 ( $M^+$ , C<sub>18</sub>H<sub>15</sub>NO<sup>+</sup><sub>4</sub>; calc. 309.1001).

*12-Methoxybenzo[b]naphtho[2,1-f]oxepine-8-carbonitrile* (**4k**). Compound **4k** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 50:1). Yellow power. M.p. 172–173°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 9.03 (d, J = 8.4, 1 H); 8.00 (s, 1 H); 7.95 (d, J = 8.4, 1 H); 7.80 (d, J = 8.5, 1 H); 7.73–7.63 (m, 2 H); 7.51 (d, J = 8.5, 1 H); 7.32–7.28 (m, 2 H); 7.12–7.05 (m, 1 H); 3.96 (s, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 154.44; 151.91; 145.61; 144.25 (CH); 135.74; 128.35 (CH); 127.46 (CH); 127.35; 126.98 (CH); 126.83; 126.66 (CH); 126.53 (CH); 125.26 (CH); 123.99 (CH); 123.54; 118.72 (CH); 118.47; 115.17 (CH); 113.00; 56.16 (Me). EI-MS: 299 ( $M^+$ , 100). HR-EI-MS: 299.0948 ( $M^+$ , C<sub>20</sub>H<sub>13</sub>NO<sup>+</sup><sub>2</sub>; calc. 299.0946).

10-Methoxybenzo[6,7]oxepino[2,3-b]pyridine-6-carbonitrile (=10-Methoxy[1]benzoxepino[2,3-b]pyridine-6-carbonitrile; **41**). Compound **41** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 5:1). Yellowish powder. M.p. 152–153°. IR (KBr): 2221.59 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 8.44 (d, J = 4.0, 1 H); 8.04 (d, J = 7.4, 1 H); 7.92 (s, 1 H); 7.45 (t, J = 6.0, 1 H); 7.33 (d, J = 4.2, 2 H); 7.10 (m, 1 H); 3.90 (s, 3 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 161.61; 152.70; 151.52 (CH); 144.10; 142.06 (CH); 141.50 (CH); 127.13 (CH); 126.66; 123.10; 122.97 (CH); 119.16 (CH); 118.55; 116.21 (CH); 113.90; 56.81 (Me). EI-MS: 250 ( $M^+$ , 100) HR-EI-MS: 250.0736 ( $M^+$ , C<sub>15</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup>; calc. 250.0742).

5-*Methoxybenzo[b]thieno[2,3-f]oxepine-9-carbonitrile* (= 5-*Methoxythieno[3,2-b][1]benzoxepine-9-carbonitrile*; **4m**). Compound **4m** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 5:1). Yellow powder. M.p. 180–181°. IR (KBr): 2211.95 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.95 (d, J = 5.4, 1 H); 7.86 (d, J = 0.5, 1 H); 7.34–7.25 (m, 2 H); 7.07–6.99 (m, 1 H); 6.96 (dd, J = 5.4, 0.5, 1 H); 3.87 (s, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 158.25; 151.64; 144.11; 137.01 (CH); 133.41 (CH); 127.38; 126.30 (CH); 122.48; 121.55 (CH); 119.06 (CH); 118.65; 115.42 (CH); 109.54; 56.28 (Me). EI-MS: 255 ( $M^+$ , 100). HR-EI-MS: 255.0354 ( $M^+$ , C<sub>14</sub>H<sub>9</sub>NO<sub>2</sub>S<sup>+</sup>; calc. 255.0354).

7-(*Trifluoromethyl*)*dibenzo*[b,f]*oxepine-10-carbonitrile* (**4n**). Compound **4n** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). Yellow powder. M.p. 108–110°. IR (KBr): 2219.67 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 8.10–8.01 (*m*, 1 H); 7.88–7.68 (*m*, 3 H); 7.66–7.46 (*m*, 3 H); 7.42–7.30 (*m*, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 157.16; 156.57; 145.50 (CH); 138.35; 133.99 (CH); 132.08 (*d*, J = 32, C-CF<sub>3</sub>); 131.31 (CH); 129.74; 129.00 (CH); 126.02 (*d*, J = 273, CF<sub>3</sub>); 126.17 (CH); 122.87 (*d*, J = 3, CH–C–CF<sub>3</sub>); 121.69 (CH); 119.36 (CH–C–CF<sub>3</sub>); 117.86; 114.52. EI-MS: 287 (*M*<sup>+</sup>, 100). HR-EI-MS: 287.0554 (*M*<sup>+</sup>, C<sub>16</sub>H<sub>8</sub>F<sub>3</sub>NO<sup>+</sup>; calc. 287.0558).

2-*Chloro-7-(trifluoromethyl)dibenzo*[b,f]*oxepine-10-carbonitrile* (**40**). Compound **40** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100 : 1). Yellow powder. M.p. 176–177°. IR (KBr): 2221.59 (CN). <sup>1</sup>H-NMR (400 MHz, (D<sub>6</sub>)DMSO): 8.02 (*s*, 1 H); 7.89 (*s*, 1 H); 7.76–7.73 (*m*, 2 H); 7.69–7.64 (*m*, 2 H); 7.52 (*d*, J = 8.3, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 161.59; 161.03; 149.21 (CH); 138.52 (CH); 137.52 (*d*, J = 32, C–CF<sub>3</sub>); 135.59 (CH); 135.28; 134.62; 134.41 (CH); 134.14; 128.43 (*d*, J = 271, CF<sub>3</sub>); 128.77 (CH); 128.32 (*d*, J = 4.0, CH–C–CF<sub>3</sub>); 124.65 (*d*, J = 4.0, CH–C–CF<sub>3</sub>); 122.78; 117.65. EI-MS: 321 ( $M^+$ , 100). HR-EI-MS: 321.0159 ( $M^+$ , C<sub>16</sub>H<sub>7</sub>ClF<sub>3</sub>NO<sup>+</sup>; calc. 321.0168).

2-*Methoxy*-7-(*trifluoromethyl*)*dibenzo*[b,f]*oxepine-10-carbonitrile* (**4p**). Compound **4p** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 50:1). Yellowish powder. M.p. 181–182°. IR (KBr): 2221.59 (CN). <sup>1</sup>H-NMR (400 MHz, (D<sub>6</sub>)DMSO): 8.02 (*s*, 1 H); 7.83 (*s*, 1 H); 7.75–7.68 (*m*, 2 H); 7.40 (*d*, J=8.8, 1 H); 7.16 (*dd*, J=8.8, 3.1, 1 H); 7.12 (*d*, J=3.1, 1 H); 3.75 (*s*, 3 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 156.92; 156.67; 150.83; 145.38 (CH); 132.10 (*d*, J=33, *C*–CF<sub>3</sub>), 129.69; 129.06 (CH); 127.94; 123.32 (*d*, J=272, CF<sub>3</sub>); 122.74 (*d*, J=3.0, CH–C–CF<sub>3</sub>); 122.51 (CH); 119.25 (CH); 119.17 (*d*, J=3.0, CH–C–CF<sub>3</sub>); 117.89; 115.15 (CH); 111.51; 55.71 (Me). EI-MS: 317 (*M*<sup>+</sup>, 100). HR-EI-MS: 317.0656 (*M*<sup>+</sup>, C<sub>17</sub>H<sub>10</sub>F<sub>3</sub>NO<sub>2</sub><sup>+</sup>; calc. 317.0664).

*8-Bromodibenzo[b*,f*]oxepine-10-carbonitrile* (**4q**). Compound **4q** was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). Light yellow powder. M.p.  $172-173^{\circ}$ . <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.98 (*s*, 1 H); 7.72 (*dd*, J = 8.6, 2.4, 1 H); 7.61-7.53 (*m*, 2 H); 7.51 (*dd*, J = 7.7, 1.3, 1 H); 7.39-7.33 (*m*, 2 H); 7.31 (*td*, J = 7.6, 1.2, 1 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 157.79; 156.44; 145.19 (CH); 135.44 (CH); 134.31 (CH); 131.74 (CH); 130.34 (CH); 128.33; 127.96; 126.53 (CH); 124.82 (CH);

122.01 (CH); 118.42; 111.46. EI-MS: 297, 299 (*M*<sup>+</sup>, 100). HR-EI-MS: 296.9789 (*M*<sup>+</sup>, C<sub>15</sub>H<sub>8</sub>BrNO<sup>+</sup>; calc. 296.9789).

8-Bromo-2-chlorodibenzo/b,f]oxepine-10-carbonitrile (4r). Compound 4r was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). White powder. M.p. 194-195°. <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 7.92 (*s*, 1 H); 7.75 (*dd*, *J* = 8.1, 1.8, 1 H); 7.65 – 7.57 (*m*, 3 H); 7.43 – 7.35 (*m*, 2 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 156.47; 156.27; 143.68 (CH); 135.77 (CH); 133.64 (CH); 130.83 (CH); 130.53 (CH); 130.42; 129.54; 128.00; 124.84 (CH); 123.88 (CH); 118.68; 118.12; 112.76. EI-MS: 331, 333 (M<sup>+</sup>, 100). HR-EI-MS: 330.9399 (*M*<sup>+</sup>, C<sub>15</sub>H<sub>7</sub>BrClNO<sup>+</sup>; calc. 330.9400).

8-Bromo-2-methoxydibenzo/b,f]oxepine-10-carbonitrile (4s). Compound 4s was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 100:1). Light yellow powder. M.p. 175-176°. <sup>1</sup>H-NMR (300 MHz,  $(D_6)$ DMSO): 7.91 (s, 1 H); 7.71 (dd, J = 8.6, 2.3, 1 H); 7.56 (d, J = 2.3, 1 H); 7.33 (d, J = 8.6, 1 H); 7.28 (d, J=8.7, 1 H); 7.10 (m, 2 H); 3.72 (s, 3 H). <sup>13</sup>C-NMR (125 MHz, (D<sub>6</sub>)DMSO): 157.04; 156.77; 151.45; 145.03 (CH); 135.44 (CH); 130.37 (CH); 128.49; 128.26; 124.64 (CH); 122.78 (CH); 119.53 (CH); 118.41; 118.22; 115.57 (CH); 111.78; 56.17 (Me). EI-MS: 327, 329 (M<sup>+</sup>, 100). HR-EI-MS: 326.9896 (M<sup>+</sup>,  $C_{16}H_{11}BrNO_{2}^{+}$ ; calc. 326.9895).

5H-Dibenzo/b,f/azepine-10-carbonitrile (4t) [30]. Compound 4t was obtained after the purification by FC (SiO<sub>2</sub>; PE/AcOEt 3:1). Brown powder. M.p. 218-219°. IR (KBr): 2217.74 (CN). <sup>1</sup>H-NMR (300 MHz, (D<sub>6</sub>)DMSO): 12.61 (s, 1 H); 8.03-7.96 (m, 2 H); 7.67-7.51 (m, 5 H); 7.33 (td, J=7.2, 1.1, 1 H); 7.26 (*td*, *J* = 7.2, 1.1, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 144.74; 135.51; 129.98 (CH); 129.33 (CH); 129.33 (CH); 129.33; 128.26; 126.97 (CH); 126.97 (CH); 123.93 (CH); 122.05 (CH); 118.37 (CH); 117.00; 112.66 (CH). EI-MS: 218 ( $M^+$ , 100). HR-EI-MS: 218.0846 ( $M^+$ ,  $C_{15}H_{10}N_2^+$ ; calc. 218.0844).

This work was financially supported by the 'Interdisciplinary Cooperation Team' Program for Science and Technology Innovation of the Chinese Academy of Sciences, the National Natural Science Foundation of China (21072205, SIMM1203ZZ-0103, and SIMM1105KF-02).

## REFERENCES

- [1] E. Tojo, D. Dominguez, L. Castedo, Phytochemistry 1991, 30, 1005.
- [2] T.-X. Qian, L.-N. Li, Phytochemistry 1992, 31, 1068.
- [3] Y.-H. Lu, C.-N. Lin, H.-H. Ko, S.-Z. Yang, L.-T. Tsao, J.-P. Wang, Helv. Chim. Acta 2003, 86, 2566.
- [4] P. Kittakoop, S. Nopichai, N. Thongon, P. Charoenchai, Y. Thebtaranonth, Helv. Chim. Acta 2004, 87, 175.
- [5] L.-H. Mu, J.-B. Li, J.-Z. Yang, D.-M. Zhang, J. Asian Nat. Prod. Res. 2007, 9, 649.
- [6] G. R. Pettit, A. Numata, C. Iwamoto, Y. Usami, T. Yamada, H. Ohishi, G. M. Cragg, J. Nat. Prod. 2006, 69, 323.
- [7] D. Acton, G. Hill, B. S. Tait, J. Med. Chem. 1983, 26, 1131.
- [8] W. S. Riehen, H. B. Basel, US Pat. 3641056, 1972.
- [9] A. A. Trabanco, J. M. Alonso, J. I. Andérs, J. M. Cid, J. Fernández, L. Iturrino, A. Megens, Chem. Pharm. Bull. 2004, 52, 262.
- [10] M. N. Agnew, A. Rizwaniuk, H. H. Ong, J. K. Wichmann, J. Heterocycl. Chem. 1986, 23, 265.
- [11] K. Hino, H. Nakamura, S. Kato, A. Irie, Y. Nagai, H. Uno, Chem. Pharm. Bull. 1988, 36, 3462. [12] R. Rupčić, M. Modrić, A. Hutinec, A. Čikoš, B. Stanić, M. Mesić, D. Pešić, M. Merćep, J. Heterocycl.
- Chem. 2010, 47, 640. [13] I. Ueda, Y. Sato, S. Maeno, S. Umio, Chem. Pharm. Bull. 1978, 26, 3058.
- [14] J. Fernández, J. M. Alonso, J. I. Andrés, J. M. Cid, A. Díaz, L. Iturrino, P. Gil, A. Megens, V. K. Sipido, A. A. Trabanco, J. Med. Chem. 2005, 48, 1709.
- [15] A. A. Trabanco, J. M. Alonso, J. M. Cid, L. M. Font, A. Megens, Farmaco 2005, 60, 241.
- [16] R. Kiyama, T. Honma, K. Hayashi, M. Ogawa, M. Hara, M. Fujimoto, T. Fujishita, J. Med. Chem. 1995, 38, 2728.
- [17] S. Jinno, T. Okita, Heterocycles 1999, 51, 303.
- [18] P. A. C. Cloos, F. Reissig, P. Boissy, M. Stahlhut, PCT Int. Appl. WO2004039773.

- [19] K. Zimmermann, S. Roggo, E. Kragten, P. Fürst, P. Waldmeier, Bioorg. Med. Chem. Lett. 1998, 8, 1195.
- [20] K. Zimmermann, P. C. Waldmeier, W. G. Tatton, Pure Appl. Chem. 1999, 71, 2039.
- [21] P. G. Nantermet, H. A. Rajapakse, PCT Int. Appl. WO2007019080.
- [22] R. H. F. Manske, A. E. Ledingham, J. Am. Chem. Soc. 1950, 72, 4797.
- [23] F. A. L. Anet, P. M. G. Bavin, Can. J. Chem. 1957, 35, 1084.
- [24] R. Olivera, R. SanMartin, F. Churruca, E. Domínguez, J. Org. Chem. 2002, 67, 7215.
- [25] Z. Yang, H. N. C. Wong, P. M. Hon, H. M. Chang, C. M. Lee, J. Org. Chem. 1992, 57, 4033.
- [26] T. Storz, E. Vangrevelinghe, P. Dittmar, Synthesis 2005, 15, 2562.
- [27] Z. Cong, T. Miki, O. Urakawa, H. Nishino, J. Org. Chem. 2009, 74, 3978.
- [28] N. B. Chernysheva, A. V. Samet, V. N. Marshalkin, V. A. Polukeev, V. V. Semenov, *Mendeleev Commun.* 2001, 11, 109.
- [29] Y. Chen, H. Xiang, Y. Xie, C. Yang, Heterocycles 2011, 83, 1355.
- [30] H. Blattner, A. Storni, Pat. EP 0011603 A1, 1980.
- [31] P. M. G. Bavin, K. D. Bartle, D. W. Jones, J. Heterocycl. Chem. 1968, 5, 327.

Received March 8, 2012